Cell Study Reveals Tenofovir and Dolutegravir Halt HTLV-1 Spread in the Body
An international research team has made a significant breakthrough, discovering a method to suppress the transmission of HTLV-1. This lesser-known but highly dangerous virus affects approximately 10 million people worldwide. The findings of this crucial study were published in the prestigious journal, Cell.
Researchers from Australia`s Peter Doherty Institute for Infection and Immunity and WEHI have demonstrated that two existing antiretroviral drugs, Tenofovir and Dolutegravir, commonly used to treat HIV, are highly effective in halting the spread of HTLV-1 in the body. The experiments involved unique `humanized` mice, which had been engrafted with human immune cells. Treatment with these medications led to a near-complete cessation of viral replication within infected cells.
HTLV-1 targets the same T-cells as HIV and can, years after infection, lead to life-threatening conditions such as adult T-cell leukemia and myelopathy (spinal cord inflammation). Until now, no effective preventive measures or therapies existed to slow the disease`s progression.
Furthermore, the research team uncovered an innovative therapeutic approach: combining antiviral agents with MCL-1 protein inhibitors allowed for the selective elimination of infected cells. This opens promising avenues not only for virus prevention but also for potentially curing already infected individuals.
In related news, it was previously reported that scientists successfully developed a unique antibody offering protection against two other highly lethal viruses: Nipah and Hendra. Both viruses are known to cause severe lung and brain inflammation and are characterized by high mortality rates.
